Lancashire and South Cumbria SACT CRG

SACT CRG Chair: Professor Ruth Board, Consultant Medical Oncologist and SACT Lead, Lancashire Teaching Hospitals NHS Foundation Trust 

Secretary: Susan Alston susan.alston@lthtr.nhs.uk
CRG Group Contact: Rachel Lloyd rachel.lloyd@lthtr.nhs.uk

The role and purpose of the SACT CRG is to improve the experience and outcomes of cancer care for chemotherapy patients in Lancashire & South Cumbria.

This involves consideration of strategies and plans for service improvement and service development across the patient pathway, incorporating all aspects of care at appropriate stages of the patient's journey. The aim is to achieve the best possible outcomes and best quality of life for all patients who use Acute Oncology services within the Network.

Members of the group will be responsible for feeding back information/decisions from the meetings to their clinical and managerial colleagues.

The SACT protocols can be accessed via the following link:    <<<  SACT PROTOCOLS >>>

 

SACT CRG Key Documents

SACT Mutual Aid Policy (V3)

SACT CRG Key Documents

Contingency Plan for iQemo Oncology e-Prescribing System (Updated September 2020) ESMO IO Toxicity Treatment Guidance (Updated 2022) Immune-Related Adverse Event Guidelines- Hepatoxicity Immune-Related Adverse Event: Diarrhoea Colitis Pre-assessment SACT SOP v1 Standard Operating Procedure- Medical Systemic Anti-Cancer Drug Prescribing (Updated June 2023) Switching Patients from IV Atezolizumab to SC Atezolizumab Systemic Anticancer Treatment and Prescribing Competency Documentation (Review date December 2024) TNM Classification of Malignant Tumours 8th edition UKONS AO Initial Management Guidelines (Updated February 2023)

SACT CRG Clinical Guidelines

LSCCA Antiemetic Guideline (Updated February 2023) LSCCA Chemotherapy Deviation Policy v3 (Updated March 2024)) LSCCA Extravasation Policy v7.2- (Updated June 2023) LSCCA Network Guideline For The Use of Aranesp v3 (Updated February 2023) LSCCA SACT Administration Policy v7.0 (Updated March 2023) LSCCN SACT SOP v2 (Updated March 2023)

 

LSCCA Network Guidelines for The Use of Aranesp 

For a more detailed background information on prescribing please see the following guidance:
'Policy for the use of Erythropoietin's for Cancer Treatment Induced Anaemia in the Nothern Cancer Alliance'
https://northerncanceralliance.nhs.uk/wp-content/uploads/2018/11/Policy-for-the-use-of-erythropoietins-for-cancer-treatment-induced-anaemia-v1.6-Jan-2018.pdf

 

Return to header